Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibroblast activation protein-α expression in fibroblasts is common in the tumor microenvironment of colorectal cancer and may serve as a therapeutic target.

Pathology oncology research : POR·2023
Same author

A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.

Journal of cancer research and clinical oncology·2022
Same author

[Hemithyroidectomy or total thyroidectomy for low-risk papillary thyroid cancer? : Surgical criteria for primary and secondary choice of treatment in an interdisciplinary treatment concept].

Chirurgie (Heidelberg, Germany)·2022
Same author

Multimodal survival prediction in advanced pancreatic cancer using machine learning.

ESMO open·2022
Same author

[Nodular tumour of the Vas deferens with epithelial structures].

Der Pathologe·2021
Same author

Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK).

Langenbeck's archives of surgery·2021
Same journal

[Connective (tissue) pathology: What brings us together!]

Der Pathologe·2022
Same journal

[Giant cell-containing tumors of bone and differential diagnoses].

Der Pathologe·2022
Same journal

[Automation and application of robotics in the pathology laboratory].

Der Pathologe·2022
Same journal

[Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].

Der Pathologe·2022
Same journal

[Artificial intelligence: a solution for the lack of pathologists?]

Der Pathologe·2022
Same journal

[Predictive immunocytochemistry in non-small cell lung carcinoma].

Der Pathologe·2022
See all related articles

Related Experiment Videos

[Multiple endocrine neoplasia type 2].

S-Y Sheu1, K W Schmid

  • 1Institut für Pathologie und Neuropathologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45122, Essen.

Der Pathologe
|October 21, 2010
PubMed
Summary
This summary is machine-generated.

Multiple endocrine neoplasia type 2 (MEN 2) is an inherited cancer syndrome caused by RET gene mutations. Understanding mutation location is key for managing medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism in MEN 2 patients.

Related Experiment Videos

Area of Science:

  • Genetics
  • Oncology
  • Endocrinology

Background:

  • Multiple endocrine neoplasia type 2 (MEN 2) is a hereditary cancer syndrome.
  • It presents in three subtypes: MEN 2A, MEN 2B, and familial medullary thyroid carcinoma.
  • MEN 2 is characterized by medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism.

Purpose of the Study:

  • To review the morphology and clinical presentation of tumors associated with MEN 2.
  • To discuss precursor lesions in MEN 2.
  • To highlight the significance of RET proto-oncogene mutations in MEN 2 pathogenesis and clinical management.

Main Methods:

  • Literature review of MEN 2.
  • Summary of morphological and clinical data for MEN 2-associated tumors.
  • Correlation of RET proto-oncogene mutations with clinical outcomes.

Main Results:

  • Germ-line mutations in the RET proto-oncogene cause MEN 2.
  • The specific location of RET mutations influences the development and clinical course of medullary thyroid carcinoma.
  • MEN 2 subtypes (2A, 2B, FMTC) exhibit distinct clinical features.

Conclusions:

  • RET proto-oncogene mutations are central to MEN 2.
  • Understanding mutation localization is critical for predicting disease progression and guiding clinical management.
  • This review provides insights into MEN 2 tumor morphology, clinical aspects, and precursor lesions.